Cincinnati Children's Hospital
Kurome Therapeutics Raises $15 Million in Series A Financing
The preclinical company is developing dual IRAK1/4 and panFLT3 inhibitors for the treatment of acute myeloid leukemia.
The preclinical company is developing dual IRAK1/4 and panFLT3 inhibitors for the treatment of acute myeloid leukemia.